Dr. Öğr. Üyesi Cengiz Akosman

• Lung Neoplasms 6 publications
  Source: OpenAlex / PubMed MeSHView publications
• Carcinoma, Non-Small-Cell Lung 5 publications
• Breast Neoplasms 2 publications

Medical areas of interest stated by the doctor on the institution profile. Source: medicalpark.com.tr.

Experience

• 2012 - 2013Erzurum Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Klinik Sorumlu Doktorumedicalpark.com.tr
• ExperienceMedical Park Ordu Etik Kurul Üyeliğimedicalpark.com.tr
• ExperienceMedical Park Ordu Transfüzyon Komitesi Üyeliğimedicalpark.com.tr

Education

• 1994 - 2001Lisans - İÜ. Cerrahpaşa Tıp Fakültesi İngilizce Tıp Bölümümedicalpark.com.tr
• 2002 - 2007Y. Lisans - İç Hastalıkları - SB Haydarpaşa EA Hastanesimedicalpark.com.tr
• 2007 - 2010Doktora - Tıbbi Onkoloji - Yeditepe Üniversitesi Hastanesi Onkoloji Bölümümedicalpark.com.tr

• SpecialtyMedical Oncologymedicalpark.com.trFrom source
• Department name at the sourceMedikal Onkoloji (Tıbbi Onkoloji)medicalpark.com.trFrom source
• InstitutionMedical Park Ordumedicalpark.com.trFrom source
• Area of workLung NeoplasmsExtracted from 6 publications · Model version —From source
• Publications22 publicationsORCID, Europe PMC, OpenAlexFrom source
• ORCID0000-0003-3668-5550ORCIDFrom source
• Last synchronised4 November 2026 20:36https://www.medicalpark.com.tr/hekimler/cengiz-akosmanmedicalpark.com.tr

1. Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer

   Journal of Clinical Medicine, 2026

   DOI 10.3390/jcm15020642 PMID 41598581 Open-access full textSource: ORCID

2. Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients

   Scientific reports, 2026

   DOI 10.1038/s41598-026-50526-x PMID 42103792 Open-access full textSource: Europe PMC

3. The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer

   Discover oncology, 2026

   DOI 10.1007/s12672-026-04705-x PMID 41721952 Open-access full textSource: Europe PMC

4. Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab

   Scientific reports, 2026

   DOI 10.1038/s41598-026-48955-9 PMID 41981174 Open-access full textSource: Europe PMC

5. Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis

   The oncologist, 2026

   DOI 10.1093/oncolo/oyag092 PMID 41838398 Open-access full textSource: ORCID

6. Impact of renin-angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non-small cell lung cancer

   Expert review of anticancer therapy, 2026

   DOI 10.1080/14737140.2026.2615853 PMID 41511755 2 citations (Europe PMC) Source: ORCID

7. Somatic mutation profiling by NGS-based liquid biopsy in advanced non-small cell lung cancer: frequency, clinical correlates, and prognostic significance

   Molecular biology reports, 2026

   DOI 10.1007/s11033-026-11971-z PMID 42176127 1 citation (Europe PMC) Open-access full textSource: Europe PMC

8. Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group

   BMC Cancer, 2026

   DOI 10.1186/s12885-026-16667-y PMID 42693417 Open-access full textSource: OpenAlex

9. Ten-year risk of second primary malignancies among chemotherapy-treated early-stage breast cancer survivors: a multicentre cohort study from the Turkish Oncology Group

   Frontiers in Oncology, 2026

   DOI 10.3389/fonc.2026.1756315 PMID 42482752 1 citation (OpenAlex) Open-access full textSource: OpenAlex

10. Prognostic value of the Scottish Inflammatory Prognostic Score in advanced NSCLC treated with second-line nivolumab

    Discover Oncology, 2026

    DOI 10.1007/s12672-026-04859-8 PMID 42014558 Open-access full textSource: OpenAlex